Loratadine 10 mg pseudoephedrine sulfate 240 mg

Dry mouth, mild stomach upset, trouble sleeping, dizziness, headache, nervousness, loss of appetite, or thirst may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

If your doctor has directed you to use this medication, remember that your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor right away if you have any serious side effects, including: fast/irregular heartbeat, uncontrolled shaking or tremor, mental/mood changes (such as confusion), difficulty urinating.

Get medical help right away if you have any very serious side effects, including: seizures.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US - Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Severe hypertension, severe coronary artery disease, urinary retention, hyperthyroidism, narrow-angle glaucoma; history of dysphagia, known upper gastrointestinal narrowing, abnormal oesophageal peristalsis. Concomitant use or within 14 days of discontinuing MAOI.

Patient with CV disease including ischaemic heart disease and hypertension; diabetes mellitus, thyroid dysfunction, stenosing peptic ulcer, pyloroduodenal obstruction, prostatic hyperplasia, genitourinary obstruction. Patient receiving digitalis treatment. Renal and hepatic impairment. Children and elderly. Pregnancy and lactation.

Significant: CNS stimulation, excitability, convulsions or CV collapse with hypotension; drug abuse or dependence. Rarely, mechanical upper gastrointestinal tract obstruction (particularly in patients with history of dysphagia).
Cardiac disorders: Tachycardia, palpitation.
Gastrointestinal disorders: Dry mouth, abdominal distress, nausea, dyspepsia.
General disorders and administration site conditions: Fatigue, thirst.
Hepatobiliary disorders: Rarely, abnormal hepatic function.
Investigations: Increased intraocular pressure.
Metabolism and nutrition disorders: Anorexia.
Nervous system disorders: Headache, drowsiness, somnolence, dizziness, hyperkinesia.
Psychiatric disorders: Insomnia, nervousness, irritability, confusion.
Renal and urinary disorders: Urinary retention.
Respiratory, thoracic and mediastinal disorders: Cough, nasal irritation, pharyngitis, dyspnoea.
Vascular disorders: Hypertension.

This drug may cause drowsiness, if affected, do not drive or operate machinery. 

Symptoms: CNS depression (e.g. sedation, apnoea, decreased mental alertness, cyanosis, coma, CV collapse) to CNS stimulation (e.g. insomnia, hallucination, tremors, convulsions), excitement, euphoria, palpitations, tachycardia, thirst, perspiration, nausea, dizziness, tinnitus, ataxia, blurred vision and hypertension or hypotension. Management: Symptomatic and supportive treatment. Induce emesis using ipecac syrup (except in patients with impaired consciousness), then may give activated charcoal. Perform gastric lavage if vomiting is contraindicated or unsuccessful. Administer vasopressors to treat hypotension, and diazepam, short-acting barbiturates or paraldehyde to control seizures. Provide ventilatory support for apnoea.

Loratadine: Elevated plasma concentrations with ketoconazole, erythromycin and cimetidine.
Pseudoephedrine: Increased ectopic pacemaker activity with digitalis. May antagonise the antihypertensive action of methyldopa, mecamylamine, reserpine, and veratrum alkaloids. Enhanced rate of absorption with antacids.
Potentially Fatal: Pseudoephedrine: Increased risk of hypertensive crisis with MAOIs.

Loratadine: Delayed time to peak plasma concentration and increased bioavailability with food. Enhanced CNS depressant effects with alcohol.

Loratadine: May diminish the wheal and flare reactions to skin test antigens.
Pseudoephedrine: May cause false-positive result with urine detection of amphetamine.

Description: Loratadine is a long-acting, tricyclic non-sedating antihistamine. It selectively inhibits the effects of histamine H1-receptors on effector cells.
Pseudoephedrine is a sympathomimetic agent that relieves nasal congestion by directly stimulating the α-adrenergic receptors resulting in vasoconstriction of respiratory mucosa, and the β-adrenergic receptors causing relaxation of bronchial muscles, and increased heart rate and contractility.
Onset: Loratadine: 1-3 hours.
Pseudoephedrine: Decongestant effect: 30 minutes.
Duration: Loratadine: >24 hours.
Pseudoephedrine: 3-8 hours (immediate-release).
Pharmacokinetics:
Absorption: Rapidly absorbed from the gastrointestinal tract.
Loratadine: Food delays time to peak plasma concentration and increases bioavailability. Time to peak plasma concentration: Approx 1-1.5 hours (loratadine); approx 1.5-3.7 hours (desloratadine).
Pseudoephedrine: Time to peak plasma concentration: 1-3 hours (immediate-release).
Distribution: Enters breast milk.
Loratadine: Volume of distribution: 119 L/kg. Plasma protein binding: Approx 97-99% (loratadine); approx 73-76% (desloratadine).
Pseudoephedrine: Volume of distribution: 2.64-3.51 L/kg.
Metabolism: Loratadine: Extensively metabolised in the liver by CYP3A4 and CYP2D6 isoenzymes to desloratadine or descarboethoxyloratadine (active metabolite).
Pseudoephedrine: Incompletely metabolised in the liver via N-demethylation to norpseudoephredrine (active metabolite).
Excretion: Loratadine: Via urine (40%) and faeces (approx 40%) as metabolites. Elimination half-life: Loratadine: 8.4 hours (range: 3-20 hours); Desloratadine: 28 hours (range: 8.8-92 hours).
Pseudoephedrine: Via urine (43-96% as unchanged drug, 1-6% as norpseudoephedrine). Elimination half-life: 9-16 hours (pH 8); 3-6 hours (pH 5). Excretion is dependent on urine pH and flow rate; alkaline urine decreases renal elimination.

Store in a dry place between 20-25°C. Protect from light.

R01BA52 - pseudoephedrine, combinations ; Belongs to the class of systemic sympathomimetic preparations used as nasal decongestants.

Alavert Allergy Sinus D-12 Extended Release Film Coated Tablet (GlaxoSmithKline Consumer Healthcare Holdings [US] LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 07/07/2021.

Anon. Loratadine and Pseudoephedrine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/07/2021.

Anon. Loratadine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/07/2021.

Anon. Pseudoephedrine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/07/2021.

Buckingham R (ed). Loratadine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/07/2021.

Clarinase Extended Release Tablet (Bayer HealthCare Limited). MIMS Hong Kong. http://www.mims.com/hongkong. Accessed 07/07/2021.

Clarinase Repetabs (Bayer Co. [Malaysia] Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 07/07/2021.

Claritin-D 24 Hour Extended Release Tablet (Bayer Healthcare LLC.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 07/07/2021.

Loratadine; Pseudoephedrine. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 07/07/2021.

Does Loratadine

What is Loratadine

What is the generic name for Loratadine

Does loratadine 10 mg contain pseudoephedrine?